N※N

Amyris Contracts for Biofenea" Manufacture with Antibiticos, S.A.

  //health-fitness.news-articles.net/content/2011/ .. r-biofenea-manufacture-with-antibiticos-s-a.html
  Published in Health and Fitness on Friday, March 4th 2011 at 4:20 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

EMERYVILLE, Calif.--([ BUSINESS WIRE ])--Amyris, Inc. (NASDAQ:AMRS) announced today that it has entered into a contract manufacturing agreement with Antibiticos, S.A. Under this arrangement, Antibiticos will work with Amyris to produce farnesene at its facilities in Len, Spain; the produced farnesene will be owned and distributed by Amyris.

"Our initial work with Amyris has validated their technology in our facility. Additionally, we see a strong match between the two companiesa� values and vision. Antibiticos follows a very demanding and selective approach for new projects, and we are proud to use this cutting-edge technology."

This is Amyrisa�s fourth farnesene production agreement. The first was to establish a joint venture with Grupo So Martinho at their flagship mill, Usina So Martinho. In addition, Amyris has contracted for production capacity at the facilities of Biomin GMBH and Tate & Lyle Ingredients Americas, Inc., an affiliate of Tate & Lyle PLC. Finally, Amyris has entered into an agreement with Glycotech, Inc. to provide finishing services to convert the Amyris Biofene into other products, including squalane, lubricants and diesel.

Amyris and Antibiticos commenced test fermentation runs in January 2011, and, based on the successful outcome of those production runs, are proceeding with expanded production.

aThis agreement with Antibiticos should allow us to reach our target initial production levels and meet customer demand for our near-term product offerings,a said John Melo, CEO of Amyris. aWe have been very impressed with the world-class technical expertise in aseptic fermentation at Antibiticos, and are looking forward to leverage this as we build up our commercial production capability.a

aThis agreement merges our experience and technical capacity with Amyrisa�s technology and processes, and forms another important step in the strategy of diversifying our business portfolio,a said Daniele Pucci Di Benisichi, CEO of Antibiticos. aOur initial work with Amyris has validated their technology in our facility. Additionally, we see a strong match between the two companiesa� values and vision. Antibiticos follows a very demanding and selective approach for new projects, and we are proud to use this cutting-edge technology.a

About Amyris

Amyris is an integrated renewable products company focused on providing sustainable alternatives to a broad range of petroleum-sourced products. Amyris uses its industrial synthetic biology platform to convert plant sugars into a variety of hydrocarbon molecules - flexible building blocks which can be used in a wide range of products. Amyris is commercializing these products both as No Compromise� renewable ingredients in cosmetics, flavors and fragrances, polymers, lubricants and consumer products, and also as No Compromise renewable diesel and jet fuel. Amyris Brasil S.A., a subsidiary of Amyris, oversees the establishment and expansion of Amyris's production in Brazil. Amyris also has fuel distribution capabilities in the United States through its subsidiary, Amyris Fuels LLC. More information about Amyris is available at [ www.amyris.com ].

About Antibiticos

Antibiticos, S.A. is a world leader with more than 50 years listed among the leading producers of Active Pharmaceutical Ingredients (APIs). Its expertise lies in both fermentation and semi-synthesis processes where the company has become a global reference. Antibiticos, S.A. offers contract manufacturing services to multinational corporations, large pharmaceutical organizations and other companies outsourcing products for toll manufacturing. As a strong key partner of multinational pharmaceutical companies for the production of APIs, its products are sold in more than 50 countries worldwide. Antibiticos, S.A. facilities have a long record of operating in compliance with GMP, ISO 9001 certification and are FDA Approved. Its fermentation facilities are capable of using different kinds of microorganisms, including fungi, yeasts, and bacteria. The company is operating under new ownership since 2009 which has brought a firm commitment and support for expanding its biotechnology business. More information about Antibiticos S.A. is available at [ www.antibioticos-sa.com ].

Forward-Looking Statements

This release contains forward-looking statements, and any statements other than statements of historical facts could be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events (such as anticipated production of farnesene with various contract manufacturers, ability to reach target initial production levels and meet customer demand for anticipated near-term product offerings, and commercial production capability) that involve risks and uncertainties. These statements are based on managementa�s current expectations and actual results and future events may differ materially due to risks and uncertainties, including those associated with any delays or failures in production and commercialization of products and other risks detailed in the aRisk Factorsa section of Amyrisa�s final prospectus for its initial public offering, as filed on September 28, 2010 pursuant to Rule 424(b) under the Securities Act of 1933, and its quarterly report on Form 10-Q filed on November 10, 2010. Amyris disclaims any obligation to update information contained in these forward-looking statements whether as a result of new information, future events, or otherwise.

Amyris, Biofene and No Compromise are trademarks or registered trademarks of Amyris, Inc.